Frequency Exchange Corp. (TSXV: FREQ | OTC: FRECF | FSE: YC6) has announced the appointment of seasoned entrepreneur Dana Friesen to its Board of Directors, subject to TSX Venture Exchange approval. Friesen brings more than 25 years of experience spanning finance, strategy, operations, and commercialisation across public and private companies. The announcement arrives as the Vancouver-based digital wellness company describes what it calls an important period of accelerated global growth, making the board addition a signal investors may be watching closely.

Key Points

  • Frequency Exchange Corp. (TSXV: FREQ | OTC: FRECF | FSE: YC6) announced the board appointment on September 22, 2026.
  • Dana Friesen, founder and CEO of Summit Sciences, has been appointed to the Board of Directors, pending TSXV approval.
  • Friesen's firm has contributed to the acquisition, development, and exit of more than 65 companies, delivering billions of dollars in value.
  • Investors may watch for TSXV regulatory approval of the appointment and updates on the company's UAE expansion and U.S. clinic access.

Dana Friesen's Background and Strategic Fit for Frequency Exchange

Dana Friesen is described in the release as a multidisciplinary entrepreneur and human-performance specialist with over 25 years of experience. As founder and CEO of Summit Sciences, he has supported the acquisition, development, and successful exit of more than 65 companies, with clients including Fortune 500 corporations and major hospital systems. The company states his research-based methodology provides a framework for translating complex science into commercially scalable outcomes — an alignment the company says is directly relevant to its strategy in the wellness, technology, and consumer sectors.

Chairman's Commentary on Growth Milestones Converging

Stephen Davis, Chairman and CEO of Frequency Exchange, welcomed the appointment by highlighting several concurrent developments the company says are converging simultaneously: expansion into the UAE, access to more than 7,000 clinics across the United States, entry into the retail market, and the international release of a documentary featuring NIKKI™, the company's flagship wearable wellness platform. Davis characterised Friesen's appointment as timely given this stated growth phase. The company did not disclose specific financial figures or timelines associated with these initiatives in the announcement.

NIKKI Platform and Frequency Exchange's Wellness Technology Focus

Frequency Exchange describes NIKKI™ as a personalized frequency-based wearable digital wellness platform designed to support sleep, stress, recovery, energy, and overall wellbeing. Unlike conventional wearables that primarily monitor health metrics, the company states NIKKI™ delivers active frequency-based programs. Originally developed through research supporting individuals living with Lyme disease, the platform has since been repositioned as a broader scalable wellness solution addressing global health challenges across multiple commercial markets.

Regulatory Approval Requirement for the Board Appointment

Frequency Exchange confirmed that Friesen's appointment remains subject to TSX Venture Exchange approval under TSXV Policy 3.1. Required filings have been submitted, though the company cautions that there is no assurance the exchange will approve the appointment as proposed. The immediate share price impact was not clear from available public information.